Last edition
News about "Xyphos Biosciences"
Astellas Signs License Deal with Poseida to Develop Novel Allogeneic Cell Therapies
Astellas Pharma Inc. has announced that Xyphos Biosciences, Inc., a wholly owned subsidiary of Astellas and Poseida have signed a research collaboration and license agreement to develop novel convertibleCAR programs by combining the innovative cell therapy platforms from each of the companies.
Xyphos Biosciences | 03/05/2024 | By Aishwarya | 188
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members